The deficiency of C1 inhibitor and its treatment.
In this article, we review the traditional therapies of hereditary angioedema (HAE) that have been used for several years. Some of these therapies were proposed before the definition of the underlying defect and the understanding of the pathogenesis of the disease. We also describe new compounds under investigation at present as potential therapies for HAE. Two of these new therapies (a plasma-kallikrein inhibitor and a bradykinin B(2)-receptor antagonist) have been developed based on the understanding that the pathogenesis of symptoms was mainly due to kallikrein activation and bradykinin release.
Cicardi
Marco
M
Department of Internal Medicine, University of Milan, San Giuseppe Hospital A.Fa.R., Milan, Italy. Marco.Cicardi@unimi.it
Zingale
Lorenza C
LC
D000799:Angioedema / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000378:metabolism* / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans
D003174:Complement C1 Inactivator Proteins